How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer.
Publication
, Journal Article
Dent, SF; Moore, H; Raval, P; Alder, L; Guha, A
Published in: JACC CardioOncol
September 2022
• Targeted therapies improve clinical outcomes in HER2+ metastatic breast cancer. • There is thus far minimal signal of increased risk of cardiotoxicity from novel HER2 targeted therapies. • Cancer therapy benefit drives clinical decision-making with LV dysfunction. • The frequency of cardiac monitoring should be based on a risk-benefit approach.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JACC CardioOncol
DOI
EISSN
2666-0873
Publication Date
September 2022
Volume
4
Issue
3
Start / End Page
404 / 408
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Dent, S. F., Moore, H., Raval, P., Alder, L., & Guha, A. (2022). How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer. JACC CardioOncol, 4(3), 404–408. https://doi.org/10.1016/j.jaccao.2022.06.002
Dent, Susan F., Heather Moore, Priyanka Raval, Laura Alder, and Avirup Guha. “How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer.” JACC CardioOncol 4, no. 3 (September 2022): 404–8. https://doi.org/10.1016/j.jaccao.2022.06.002.
Dent SF, Moore H, Raval P, Alder L, Guha A. How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer. JACC CardioOncol. 2022 Sep;4(3):404–8.
Dent, Susan F., et al. “How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer.” JACC CardioOncol, vol. 4, no. 3, Sept. 2022, pp. 404–08. Pubmed, doi:10.1016/j.jaccao.2022.06.002.
Dent SF, Moore H, Raval P, Alder L, Guha A. How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer. JACC CardioOncol. 2022 Sep;4(3):404–408.
Published In
JACC CardioOncol
DOI
EISSN
2666-0873
Publication Date
September 2022
Volume
4
Issue
3
Start / End Page
404 / 408
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology